Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

62484

Sigma-Aldrich

Lithium citrate tribasic tetrahydrate

BioUltra, ≥99.5% (NT)

Synonym(s):

Citric acid trilithium salt, Trilithium citrate tetrahydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
HOC(COOLi)(CH2COOLi)2 · 4H2O
CAS Number:
6080-58-6
Molecular Weight:
281.98
EC Number:
213-045-8
MDL number:
MFCD00150030
UNSPSC Code:
12161700
PubChem Substance ID:
329759732
NACRES:
NA.25
Pricing and availability is not currently available.

product line

BioUltra

Quality Level

200

assay

≥99.5% (NT)

form

solid

impurities

insoluble matter, passes filter test

pH

8.0-9.5 (25 °C, 1 M in H2O)

solubility

H2O: 1 M at 20 °C, clear, colorless

anion traces

chloride (Cl-): ≤50 mg/kg
sulfate (SO42-): ≤50 mg/kg

cation traces

Al: ≤5 mg/kg
As: ≤0.1 mg/kg
Ba: ≤5 mg/kg
Bi: ≤5 mg/kg
Ca: ≤10 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤5 mg/kg
K: ≤50 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
Mo: ≤5 mg/kg
Na: ≤50 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Sr: ≤5 mg/kg
Zn: ≤5 mg/kg

λ

1 M in H2O

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
16-228MABT524CBL458
Anti-Cortactin (p80/85) Antibody, clone 4F11 clone 4F11

05-180-I

Anti-Cortactin (p80/85) Antibody, clone 4F11

Anti-Cortactin (p80/85) Antibody, clone 4F11, Alexa Fluor™ 488 clone 4F11, Upstate®, from mouse

16-228

Anti-Cortactin (p80/85) Antibody, clone 4F11, Alexa Fluor™ 488

Anti-Cortactin (p80/85) Antibody, clone 5G3.2 clone 5G3.2, from mouse

MABT524

Anti-Cortactin (p80/85) Antibody, clone 5G3.2

Anti-CD49f Antibody, clone 4F10 clone 4F10, Chemicon®, from mouse

CBL458

Anti-CD49f Antibody, clone 4F10

clone

4F11, monoclonal

clone

4F11, monoclonal

clone

5G3.2, monoclonal

clone

4F10, monoclonal

form

liquid

form

-

form

-

form

-

Quality Level

200

Quality Level

100

Quality Level

100

Quality Level

100

isotype

IgG1κ

isotype

IgG1

isotype

IgG2bκ

isotype

IgG2b

target post-translational modification

unmodified

target post-translational modification

-

target post-translational modification

unmodified

target post-translational modification

unmodified

Application

Lithium citrate is useful as a potential therapeutic for Canavan disease due to aspartoacylase deficiency or aminoacylase 2 deficiency.

Other Notes

Quantification of physiological amino acids by gradient lithium ion-exchange HPLC.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    BCCH1073
    BCCC9061
    BCBZ4546
    BCBV6100
    BCBT6543

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    S E Møller
    Journal of chromatography, 613(2), 223-230 (1993-04-02)
    A single-column gradient lithium ion-exchange chromatographic method with post-column derivatization and fluorimetric detection for the quantification of physiological amino acids is described. The method runs automatically, requires a minimum of sample preparation, separates all amino acids in plasma and cerebrospinal
    Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.
    Assadi M, Janson C, Wang DJ, et al.
    European Journal of Pediatrics, 14, 354-359 (2010)
    María Dolores Edo Solsona et al.
    Clinical neuropharmacology, 35(3), 150-151 (2012-05-18)
    Canavan disease is a rare autosomal recessive leukodystrophy characterized by abnormal accumulation of N-acetyl aspartate (NAA) in brain white matter. Currently, there is no cure for this disease, and management of patients consists mainly of treating symptoms. We describe a
    Christopher G Janson et al.
    Pediatric neurology, 33(4), 235-243 (2005-10-01)
    Current evidence suggests that the effects of lithium on metabolic and signaling pathways in the brain may vary depending on the specific clinical condition or disease model. For example, lithium increases levels of cerebral N-acetyl aspartate in patients with bipolar
    Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.
    Toni M Brand et al.
    Cancer biology & therapy, 11(3), 368-370 (2011-01-14)

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service